{
    "name": "carmustine",
    "comment": "Rx",
    "other_names": [
        "BiCNU",
        "Gliadel"
    ],
    "classes": [
        "Antineoplastics",
        "Alkylating"
    ],
    "source": "https://reference.medscape.com/drug/bicnu-gliadel-carmustine-342194",
    "pregnancy": {
        "common": [
            "Therapy can cause fetal harm when administered to a pregnant woman; there are no available data on use in pregnant women"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Drug is embryotoxic and teratogenic in rats at exposures less than exposure at recommended human dose based on body surface area (BSA) and embryotoxic in rabbits at exposures similar to exposures at the recommended human dose based on BSA; advise pregnant women of potential risk to a fetus",
                    "Verify pregnancy status of females of reproductive potential prior to therapy",
                    "Therapy can cause fetal harm when administered to a pregnant woman.",
                    "Advise females of reproductive potential to use effective contraception for 6 months after therapy",
                    "Based on its mechanism of action, advise males with female partners of reproductive potential to use effective contraception for 3 months following therapy",
                    "Carmustine caused testicular degeneration in animals; advise male patients of potential risk of infertility"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "No data are available regarding presence of drug or metabolites in human milk or effects on breastfed child or on milk production; because of potential for serious adverse reactions in breastfed children from therapy, advise women not to breastfeed following treatment and for at least 7 days after treatment"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "The drug should be administered under the supervision of an experienced cancer chemotherapy physician",
                "Bone marrow suppression (notably thrombocytopenia and leukopenia) is the most common and severe of the toxic effects that may result from carmustine administration. It may contribute to bleeding and infections; monitor blood counts for at least 6 weeks after a dose",
                "Pulmonary toxicity is dose related; risk increases with cumulative doses > 1400 mg/mÂ², history of lung disease and duration of therapy; delayed cases of pulmonary fibrosis that can result in death have been reported 15 years after administration in children"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Do not give more frequently than q6-8wk due to delayed myelosuppression; complete blood count should be monitored weekly for at least six weeks after each dose",
                "Risk of irreversible pulmonary fibrosis on long-term treatment",
                "Injection site reactions may occur during administration; rapid infusion may cause burning along the vein and flushing of skin",
                "Extravasation risk, monitor closely during infusion",
                "Ocular toxicity associated with intracarotid route (investigational); safety and efficacy not established",
                "Associated with moderate to high emetic potential; administer antiemetics to prevent nausea and vomiting",
                "Monitor liver function tests periodically during therapy; reversible increases (rare) in bilirubin, alkaline phosphatase levels, and transaminases reported",
                "Wafer implant associated with intracranial hypertension; brain edema reported in patients with newly diagnosed glioma; monitor closely for intracranial hypertension related to brain edema, inflammation, or necrosis of brain tissues surrounding resection; in refractory cases, removing the wafer may be necessary",
                "Meningitis reported in patients with recurrent glioma receiving wafer implants; monitor postoperatively for signs/symptoms of meningitis and CNS infection",
                "Renal failure, decreased kidney size, and progressive azotemia reported in patients receiving low or large cumulative doses or prolonged treatment; monitor renal function periodically",
                "Long-term use associated with development of secondary malignancies (acute leukemia and bone marrow dysplasias)",
                "Wafer implants associated with seizures; treatment-emergent seizures reported within 5 days of surgery; initiate optimal anti-seizure therapy prior to surgery",
                "Impaired neurosurgical wound healing, including wound dehiscence, delayed healing, and subdural, subgleal or wound effusions associated with wafer implant treatment; cerebrospinal fluid leaks also reported; monitor for impaired neurosurgical wound healing following surgery",
                "Avoid pregnancy"
            ],
            "specific": [
                {
                    "type": "Contraception",
                    "description": [
                        "Advise female patients to avoid pregnancy during therapy because of risk of fetal harm",
                        "Advise female patients of reproductive potential to use highly effective contraception during and for up to six months after completion of treatment",
                        "Advise males with female sexual partners of reproductive potential to use effective contraception during therapy and for at least three months after final dose of carmustine"
                    ]
                },
                {
                    "type": "Fertility",
                    "description": [
                        "Based on nonclinical findings, male fertility may be compromised by therapy"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "adenovirus types 4 and 7 live, oral",
            "description": {
                "common": "carmustine decreases effects of adenovirus types 4 and 7 live, oral by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressives may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection). Live-attenuated vaccines should be avoided for at least 3mo after cessation of immunosuppressive therapy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "axicabtagene ciloleucel",
            "description": {
                "common": "carmustine, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brexucabtagene autoleucel",
            "description": {
                "common": "carmustine, brexucabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ciltacabtagene autoleucel",
            "description": {
                "common": "carmustine, ciltacabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idecabtagene vicleucel",
            "description": {
                "common": "carmustine, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "influenza virus vaccine quadrivalent, adjuvanted",
            "description": {
                "common": "carmustine decreases effects of influenza virus vaccine quadrivalent, adjuvanted by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive drugs may reduce the immune response to influenza vaccine."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "influenza virus vaccine trivalent, adjuvanted",
            "description": {
                "common": "carmustine decreases effects of influenza virus vaccine trivalent, adjuvanted by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive drugs may reduce the immune response to influenza vaccine."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lisocabtagene maraleucel",
            "description": {
                "common": "carmustine, lisocabtagene maraleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "palifermin",
            "description": {
                "common": "palifermin increases toxicity of carmustine by Other (see comment). Avoid or Use Alternate Drug. \nComment: Palifermin should not be administered within 24 hrbefore, during infusion of, or within 24 hr after administration of antineoplastic agents. Coadministration of palifermin within 24 hr of chemotherapy resulted in increased severity and duration of oral mucositis."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ropeginterferon alfa 2b",
            "description": {
                "common": "ropeginterferon alfa 2b, carmustine.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tisagenlecleucel",
            "description": {
                "common": "carmustine, tisagenlecleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tofacitinib",
            "description": {
                "common": "carmustine, tofacitinib.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acalabrutinib",
            "description": {
                "common": "acalabrutinib, carmustine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may increase risk of myelosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belatacept",
            "description": {
                "common": "belatacept and carmustine both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bendamustine",
            "description": {
                "common": "bendamustine, carmustine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "busulfan",
            "description": {
                "common": "busulfan, carmustine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carboplatin",
            "description": {
                "common": "carboplatin, carmustine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorambucil",
            "description": {
                "common": "carmustine, chlorambucil.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cholera vaccine",
            "description": {
                "common": "carmustine decreases effects of cholera vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids (used in greater than physiologic doses), may reduce the immune response to cholera vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cimetidine",
            "description": {
                "common": "cimetidine, carmustine. Mechanism: decreasing metabolism. Use Caution/Monitor. Enhanced myelotoxicity."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cisplatin",
            "description": {
                "common": "carmustine, cisplatin.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclophosphamide",
            "description": {
                "common": "carmustine, cyclophosphamide.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dacarbazine",
            "description": {
                "common": "carmustine, dacarbazine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dengue vaccine",
            "description": {
                "common": "carmustine decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunosuppressive therapies (eg, irradiation, antimetabolites, alkylating agents, cytotoxic drugs, corticosteroids [greater than physiologic doses]) may reduce immune response to dengue vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "denosumab",
            "description": {
                "common": "carmustine, denosumab. Other (see comment). Use Caution/Monitor. \nComment: Caution should be taken in patients on concomitant immunosuppressants or with impaired immune systems because of increased risk for serious infections."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dichlorphenamide",
            "description": {
                "common": "dichlorphenamide and carmustine both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "digoxin",
            "description": {
                "common": "carmustine decreases levels of digoxin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. It is prudent to closely monitor patients for loss of clinical efficacy of digoxin while receiving antineoplastic therapy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethotoin",
            "description": {
                "common": "carmustine decreases levels of ethotoin by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fingolimod",
            "description": {
                "common": "carmustine increases effects of fingolimod by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Concomitant therapy is expected to increase the risk of immunosuppression. Use caution when switching patients from long-acting therapies with immune effects. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "carmustine decreases levels of fosphenytoin by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydroxyurea",
            "description": {
                "common": "carmustine, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ifosfamide",
            "description": {
                "common": "carmustine, ifosfamide.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza A (H5N1) vaccine",
            "description": {
                "common": "carmustine decreases effects of influenza A (H5N1) vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce immune response to H5N1 vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine (H5N1), adjuvanted",
            "description": {
                "common": "carmustine decreases effects of influenza virus vaccine (H5N1), adjuvanted by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce immune response to H5N1 vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isavuconazonium sulfate",
            "description": {
                "common": "carmustine and isavuconazonium sulfate both decrease  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lomustine",
            "description": {
                "common": "carmustine, lomustine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meningococcal group B vaccine",
            "description": {
                "common": "carmustine decreases effects of meningococcal group B vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Individuals with altered immunocompetence may have reduced immune responses to the vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ofatumumab SC",
            "description": {
                "common": "ofatumumab SC, carmustine.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Consider the risk of additive immune system effects when coadministering immunosuppressive therapies with coadministration. When switching from therapies with immune effects, take into account the duration and mechanism of action of these therapies when initiating ofatumumab SC."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "olaparib",
            "description": {
                "common": "carmustine and olaparib both increase  pharmacodynamic synergism. Use Caution/Monitor. Coadministration with other other myelosuppressive anticancer agents, including DNA damaging agents,  may potentiate and prolongate the myelosuppressive toxicity. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenytoin",
            "description": {
                "common": "carmustine decreases levels of phenytoin by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod and carmustine both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sipuleucel-T",
            "description": {
                "common": "carmustine decreases effects of sipuleucel-T by pharmacodynamic antagonism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "streptozocin",
            "description": {
                "common": "carmustine, streptozocin.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "thiotepa",
            "description": {
                "common": "carmustine, thiotepa.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trastuzumab",
            "description": {
                "common": "trastuzumab, carmustine.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trastuzumab deruxtecan",
            "description": {
                "common": "trastuzumab deruxtecan, carmustine.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vitamin A",
            "description": {
                "common": "vitamin A, carmustine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vitamin E",
            "description": {
                "common": "vitamin E, carmustine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Convulsions",
            "percent": "19"
        },
        {
            "name": "Hemiplegia",
            "percent": "19"
        },
        {
            "name": "Headache",
            "percent": "15"
        },
        {
            "name": "Metabolic disorder",
            "percent": "14"
        },
        {
            "name": "Somnolence",
            "percent": "14"
        },
        {
            "name": "Fever",
            "percent": "12"
        },
        {
            "name": "Confusion",
            "percent": "10"
        },
        {
            "name": "Aphasia",
            "percent": "9"
        },
        {
            "name": "Nausea",
            "percent": "8"
        },
        {
            "name": "Vomiting",
            "percent": "8"
        },
        {
            "name": "Pain",
            "percent": "7"
        },
        {
            "name": "Rash",
            "percent": "5"
        },
        {
            "name": "Abscess",
            "percent": "4"
        },
        {
            "name": "Cranial edema",
            "percent": "4"
        },
        {
            "name": "ICP elevation",
            "percent": "4"
        },
        {
            "name": "Meningitis",
            "percent": "4"
        },
        {
            "name": "Hyperglycemia",
            "percent": "3"
        },
        {
            "name": "HTN",
            "percent": "3"
        },
        {
            "name": "Constipation",
            "percent": "2"
        },
        {
            "name": "Diarrhea",
            "percent": "2"
        },
        {
            "name": "Dizziness",
            "percent": "2"
        },
        {
            "name": "Depression",
            "percent": "2"
        },
        {
            "name": "Greater myelotoxicity reported when coadministered with cimetidine",
            "percent": null
        },
        {
            "name": "Cardiac disorders",
            "percent": null
        },
        {
            "name": "Tachycardia and chest pain",
            "percent": null
        },
        {
            "name": "Eye disorders",
            "percent": null
        },
        {
            "name": "conjunctival edema",
            "percent": null
        },
        {
            "name": "conjunctival hemorrhage",
            "percent": null
        },
        {
            "name": "blurred vision and loss of depth perception",
            "percent": null
        },
        {
            "name": "Gastrointestinal toxicity",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "vomiting",
            "percent": null
        },
        {
            "name": "anorexia",
            "percent": null
        },
        {
            "name": "and diarrhea",
            "percent": null
        },
        {
            "name": "Hepatotoxicity",
            "percent": null
        },
        {
            "name": "Increased transaminase",
            "percent": null
        },
        {
            "name": "increased alkaline phosphatase",
            "percent": null
        },
        {
            "name": "increased bilirubin levels Infections and Infestations",
            "percent": null
        },
        {
            "name": "Infections",
            "percent": null
        },
        {
            "name": "Opportunistic infections",
            "percent": null
        },
        {
            "name": "including with fatal outcome",
            "percent": null
        },
        {
            "name": "Neoplasms benign",
            "percent": null
        },
        {
            "name": "malignant and unspecified",
            "percent": null
        },
        {
            "name": "including cysts and polyps",
            "percent": null
        },
        {
            "name": "Acute leukemia",
            "percent": null
        },
        {
            "name": "bone marrow dysplasias",
            "percent": null
        },
        {
            "name": "Nephrotoxicity",
            "percent": null
        },
        {
            "name": "Progressive azotemia",
            "percent": null
        },
        {
            "name": "decrease in kidney size",
            "percent": null
        },
        {
            "name": "renal failure",
            "percent": null
        },
        {
            "name": "Nervous system disorders",
            "percent": null
        },
        {
            "name": "Headaches",
            "percent": null
        },
        {
            "name": "encephalopathy",
            "percent": null
        },
        {
            "name": "and seizures",
            "percent": null
        },
        {
            "name": "Pulmonary toxicity",
            "percent": null
        },
        {
            "name": "Pneumonitis",
            "percent": null
        },
        {
            "name": "interstitial lung disease",
            "percent": null
        },
        {
            "name": "Reproductive system and breast disorders",
            "percent": null
        },
        {
            "name": "Gynecomastia",
            "percent": null
        },
        {
            "name": "Skin and subcutaneous tissue disorders",
            "percent": null
        },
        {
            "name": "Burning sensation",
            "percent": null
        },
        {
            "name": "hyperpigmentation",
            "percent": null
        },
        {
            "name": "swelling",
            "percent": null
        },
        {
            "name": "pain",
            "percent": null
        },
        {
            "name": "erythema",
            "percent": null
        },
        {
            "name": "skin necrosis",
            "percent": null
        },
        {
            "name": "alopecia",
            "percent": null
        },
        {
            "name": "allergic reaction",
            "percent": null
        },
        {
            "name": "Vascular Disorders",
            "percent": null
        },
        {
            "name": "Veno",
            "percent": null
        },
        {
            "name": "occlusive disease",
            "percent": null
        }
    ]
}